-- We regret to inform you that due to unforeseen circumstances beyond our control, we have had to cancel Dr. Ben Sessa's public lecture in Sydney next Thursday evening 16 Nov. 2023. We understand the inconvenience this may cause and sincerely apologise for any disappointment it may bring. However, we would like to extend a special offer to you in lieu of this cancellation. We invite you to join Dr. Ben Sessa's half-day workshop, an enlightening session designed for clinicians, professionals, and leaders interested in Psychedelic-Assisted Therapies. BOOK HERE>> --

Public Lecture presented by Mind Medicine Australia featuring Dr Ben Sessa (UK):

Psychedelic-Assisted Therapies: The New Frontier in Mental Health Treatments.

Mind Medicine Australia is delighted to present an International Public Lecture featuring renowned psychiatrist and researcher, Dr Ben Sessa (UK), live in person.

Dr Sessa has been at the forefront of psychedelic research for over 15 years through his affiliations with Bristol University and Imperial College London, under the auspices of Professor David Nutt. He brings a wealth of knowledge to this fast developing field in Australia.

In this lecture, he will explain:

What psychedelic drugs are
Safety of psychedelic drugs in the treatment of depression, trauma, eating disorders, addictions and other conditions
Psychedelics and Neuroplasticity
How psychedelic-assisted therapies work clinically?
Protocols for delivering psychedelic-assisted therapy safely and effectively
And lots more…

After Dr Sessa’s lecture, he’ll be joined onstage by a panel for discussion and Q&A with the audience. Guests will be treated to a Special Song by Soprano Tania de Jong and some themed gifts from our partners.

Tickets are strictly limited. Please register now to secure your seat.

EVENT DETAILS

DATE: Thursday 16 November 2023
TIME: 6:30pm start, finishing at 8:30pm
DURATION:120 minutes (incl Q&A)
LOCATION: Sydney University, Susan Wakill Health Building, Julie Wu Lecture Theatre, 321

ABOUT THE PRESENTER

Dr Ben Sessa (UK)

Psychiatrist, Researcher and Writer

For over 15 years Dr Ben Sessa has been at the forefront of psychedelic and cannabis research and clinical medicine in the UK through his affiliations with Imperial College London. Ben qualified as a medical doctor from UCL in 1997 and went on to specialise in psychiatry. For 25 years he has worked as a consultant child and adolescent psychiatrist with young people and adult patients in the field of addictions and trauma-related psychiatry.

Ben started studying psychedelics as a junior doctor and has taken part in research projects at Bristol University, Cardiff University and Imperial College London with LSD, psilocybin, DMT, ketamine and MDMA – receiving and/or administering all of these compounds in legal research settings.

One of the first doctors to develop the field of contemporary psychedelic research in the UK, he was the former co-founder, former CEO, and subsequently the former Head of Psychedelic Medicine at Awakn Life Sciences, a Bio-Tech company carrying out psychedelic research into addictions. Awakn opened four clinical centres in the U.K. and Europe, providing psychedelic psychotherapy with ketamine, for a wide range of psychiatric indications, as well as an extensive R&D psychedelic research program.

Ben was one of the first Medical Cannabis psychiatric prescribers in the UK.

Ben is a trained MDMA, ketamine and psilocybin therapist. He has led research into MDMA-assisted therapy for Alcohol Use Disorder and is published widely in the academic and medical press.

Ben is the co-founder and past president of the Breaking Convention conference. He is the author of The Psychedelic Renaissance (2012/2017), the novel ‘To Fathom Hell or Soar Angelic’ (2015) and Altered States (2021). Ben lives and works in Bristol, UK.

PANEL PARTCIPANTS

Dr Ted Cassidy

Psychiatrist and Co-Founder of TMS Australia

Dr Ted Cassidy is a Founder of TMS Australia – Australia’s largest provider of outpatient Depression & PTSD treatment using innovative Transcranial Magnetic Stimulation (TMS) technology. He is Chief Medical Officer and a Director of TMS Australia. He is responsible for the clinical operations and patient care in TMS Australia’s outpatient treatment centres.

Dr Cassidy previously founded The Hills Clinic group. The Hills Clinic Hospital was the first purpose built private mental health hospital in Australia when it opened in 2011. Dr Cassidy is a Psychiatrist, Fellow of the Royal Australian and New Zealand College of Psychiatrists and medical graduate of the University of Sydney.

Dr David Graham

Psychiatrist

Dr David Graham is a Psychiatrist and Psychotherapist. He has clinical and research interests in psychodynamic psychotherapy, psychopharmacology (including psychedelic-assisted therapy), veteran and first responder mental health, and therapeutic jurisprudence. He holds an academic appointment at the University of Sydney and has published over a dozen papers and presented at local and international conferences. He is active in the governance of the Royal Australian and New Zealand College of Psychiatrists through his work on the Bi-national Faculty of Psychotherapy Committee. Prior to his career in medicine, Dr Graham was a decorated defence analyst with over a decade of experience providing advice and leading research in the lab and on the battlefield.

Tania de Jong AM
Founder & Executive Director of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 4 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.

Peter Hunt AM
Founder & Chair of Mind Medicine Australia

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.

Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He founded Women’s Community Shelter in 2011 and remains on the Board. He was previously Chairman of So They Can, Grameen Australia and Grameen Australia Philippines. Peter is a Director of Project Rozana and an Advisory Board member of the Monash Sustainable Development Institute. Peter also acts as a pro bono adviser to Creativity Australia.

Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

---

MEDICINAL PSYCHEDELIC TREATMENTS

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

SUPPORT PSYCHEDELIC RESEARCH AND THERAPY DEVELOPMENT

Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.

DISCLAIMER

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.